Shane Ward - 31 Mar 2022 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: CHIEF LEGAL OFFICER
Signature: /s/ Shane Ward
Issuer symbol: CDTX
Transactions as of: 31 Mar 2022
Net transactions value: -$19,191
Form type: 4
Filing time: 04 Apr 2022, 17:12:37 UTC
Previous filing: 27 Aug 2021
Next filing: 13 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CDTX	Common Stock	Award	$0	+35,000		$0.000000	35,000	31 Mar 2022	Direct	F1
transaction	CDTX	Common Stock	Award	$0	+69,027	+197%	$0.000000	104,027	31 Mar 2022	Direct	F2
transaction	CDTX	Common Stock	Tax liability	$19,191	-23,122	-22%	$0.8300	80,905	31 Mar 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDTX	Employee Stock Option (right to buy)	Award	$0	+70,000		$0.000000	70,000	31 Mar 2022	Common Stock	70,000	$0.8300	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents time-based Restricted Stock Units (RSUs) granted on March 31, 2022. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2023, 2024, and 2025, subject to continuous service through each such vesting date.
F2	Represents RSUs granted on March 31, 2022. All RSUs are fully vested as of the grant date.
F3	Shares withheld for taxes on RSU vesting.
F4	The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022.